N4 Pharma is a pre-clinical stage specialist pharmaceutical company developing Nuvec®, a unique novel silica nanoparticle technology with patented spiky structure designed to load, protect and deliver nucleic acids (siRNA/DNA/mRNA) intracellularly for use in as gene therapy, cancer therapeutics and vaccines. Established in 2014 and floated on the AIM stock market in May 2017.
Nuvec® is currently in the pre-clinical phase, available for licensing to pharmaceutical and biotech partners for nucleic acid product development and is designed to overcome some of the drawbacks of existing delivery systems.
Learn more
Watch our new video animation below to see Nuvec® in action:
Latest news and updates
N4 Pharma’s novel delivery systems, Nuvec® and LipTide®, advance towards commercialisation
Our latest news release for trade media highlights our pre-clinical siRNA delivery systems Nuvec® and LipTide®. LipTide® is a lipid and peptide-based delivery system developed by Nanogenics and is currently being used in the formulation [...]
Article: A drug delivery strategy emerges that has the potential to transform cancer therapy
In our latest article, we look at how the dual delivery of siRNA – via delivery systems such as Nuvec® – holds the potential to pave the way for a new era of improved efficiency [...]
Independent appraisal of N4 Pharma’s Nuvec® platform by EpiVax consultant
N4 Pharma’s Nuvec® platform has been independently appraised by Dr. Amy S. Rosenberg, Senior Director of Immunology and Protein Therapeutics at EpiVax. In the report Dr. Rosenberg assesses how N4 Pharma’s breakthrough Nuvec® platform might [...]